Clinical analysis of assistant treatment proposals for infertile women with polycystic ovary syndrome

( views:267, downloads:0 )
Author:
CHEN Zi-jiang(Reproductive Medicine Center of Provincial Hospital Affiliated to Shandong University,Jinan 250021,China)
SHI Yu-hua(Reproductive Medicine Center of Provincial Hospital Affiliated to Shandong University,Jinan 250021,China)
LI Yuan(Reproductive Medicine Center of Provincial Hospital Affiliated to Shandong University,Jinan 250021,China)
GAO Qin(Reproductive Medicine Center of Provincial Hospital Affiliated to Shandong University,Jinan 250021,China)
SHENG Yan(Reproductive Medicine Center of Provincial Hospital Affiliated to Shandong University,Jinan 250021,China)
MA Zeng-xiang(Reproductive Medicine Center of Provincial Hospital Affiliated to Shandong University,Jinan 250021,China)
Journal Title:
CHINESE JOURNAL OF OBSTETRICS AND GYNECOLOGY
Issue:
Volume 43, Issue 08, 2008
DOI:
Key Word:
Polycystic ovary syndrome;Infertility, female;Reproductive techniques, assisted;Treatment outcome

Abstract: Objective To study the clinical outcomes of assistant treatment proposals for infertile women with polycystic ovary syndrome (PCOS). Methods PCOS patients were divided into four groups according to the assistant treatment proposals between Jan 2003 and Dec 2007 in Reproductive Medicine Center of the Provincial Hospital Affiliated to Shandong University. The four proposals were letrozole(LE) or clomiphene(CC) citrate ovulation induction group, in vitro fertilization and embryo transplantation group, ultrasound-guided immature follicle puncture group, and in vitro maturation and fertilization of oocytes from unstimulated cycles group. The treatment results were analyzed. Results (1) The ovulation rate was 66% (38/58) vs 47% (21/45). The mean endometrial thickness [ (0. 89±0. 13) vs (0. 78±0. 08) cm] and cervical mucus score (11.9±1.8 vs 9. 9±1.8 ) on the day of human chorionic gonadotropin ( hCG ) administration in LE group were both higher than that in CC group, while mature follicle ( 1.08±0. 28 vs 1.73±0. 59) and serum estradiol level [ (983±138) vs (1676±372) pmol/L] in LE group were lower than that in CC group(P <0. 05). (2) One southend five hundred and eighty-four patients accepted in vitro fertilization-embryo transplantation therapy because of PCOS (PCOS group) and 1615 patients because of tube factors (control group). The patients′ ages and infertility years were matched between the two groups. Total doses of Gn [ (980±1192) vs ( 1194±1389) IU] of PCOS group were lower than those of control group. The mean days of using gonadotropin [ (9.6±1.8) vs (9. 5±1. 8) d], serum estradiol (E2) levels on the hCG day [ ( 15 752±6206) vs (9675±4818) pmol/L], mean obtained oocytes (21±6 vs 9±3), mean fertilized oocytes ( 15±6 vs 7±3) and mean cleavaged oocytes ( 12. 9±5.7 vs 5.7±2. 8 ) of PCOS group were higher than those of the control group( P < 0. 05 ). Moderate and severe ovarian hyperstimulation syndrome (OHSS) rates (4. 86% vs 1.67% ) of PCOS group were higher than that of the control group. The pregnant rate (44. 7% vs 45.0% ) of PCOS group was similar to the control group ( P > 0. 05 ). (3) One hundred and nine PCOS patients were given ultrasound-guided immature follicle puncture therapy. After treatment, the testosterone level, luteinizing hormone (LH) level and LH/follicle stimulating hormone (FSH) ratio of the patients became normal. The basic follicle number decreased. (4) A total of 304 in vitro maturation cycles were performed. After embryo transfer, 76 pregnancies were reported. Conclusions There are many choices for the infertile patients with PCOS, such as LE or CC citrate ovulation induction, in vitro fertilization and embryo transplantation, ultrasound-guided immature follicle puncture, and in vitro maturation and fertilization of oocytes from unstimulated cycles. We can provide individualized treatment according to the medical treatment conditions, doctors′ professional capability and the patients′ situation.

  • [1]The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS).Hum Reprod,2004,19:41-47.
  • [2]Holzer H,Casper R,Tulandi T.A new era in ovulation induction.Fertil Steril,2006,85:277-284.
  • [3]Shozu M,Sebastian S,Takayama K,et al.Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene.N Engl J Med,2003,348:1855-1865.
  • [4]Vendola K,Zhou J,Wang J,et al.Androgens promote oocyte insulin-like growth factor Ⅰ expression and initiation of follicle development in the primate ovary.Biol Reprod,1999,61:353-357.
  • [5]李媛,陈子江,赵力新,等.超声引导下TMFP技术治疗多囊卵巢综合征无排卵性不孕的临床研究.山东医药,2004,44:15-17.
  • [6]李媛,陈子江,赵力新,等.表皮生长因子和促性腺激素对人类卵母细胞体外成熟的影响.中华男科学,2004,10:257-259.
  • [7]Chian RC,Gülekli B,Buckett WM,et al.Priming with human chorionic gonadotropin before retrieval of immature oocytes in women with infertility due to the polycystic ovary syndrome.N Engl J Med,1999,341:1624-1626.
  • [8]Child TJ,Abdul-Jalil AK,Gulekli B,et al.In vitro maturation and fertilization of oocytes from unstimulated normal ovaries,polycystic ovaries,and women with polycystic ovary syndrome.Fertil Steril,2001,76:936-942.
  • [9]陈子江.高度重视多囊卵巢综合征的规范化诊断和治疗.中华妇产科杂志,2007,42:289-290.
  • [10]陈子江.多囊卵巢综合症相关病因及临床研究:来自山东大学生殖医学中心的报告.生殖医学杂志,2007,16:232-235.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn